American Society of Hematology

ASH is the leader in representing the interests of scientists and clinicians working in the field of hematology on Capitol Hill and within federal agencies concerned with the study and treatment of blood-related diseases.


SCD Initiative 

Sickle Cell Disease Initiative

A multi-faceted initiative to identify the highest priority actions needed to improve the outcomes for individuals with SCD in the U.S. and globally.

Fight for Hematology 

Support Medical Research

Urge your members of Congress to support continued medial research funding.

Advocacy Leadership Institute

Provides opportunities to learn more about advocacy, health policy, and the legislative process, and to become engaged in the Society’s activities.

Congressional Fellowship

Provides education about the policy making process, including Congress’ relationship to the hematology community.

MACRA Resources

Get an overview of the Medicare Access and CHIP Reauthorization Act (MACRA) and its impact on hematology.

Drug Access Issues

Keep informed of newly approved therapies, safety and prescription matters, and shortages of critical hematologic drugs.

CAC Networking Meeting

Learn about the yearly ASH-ASCO Carrier Advisory Committee (CAC) Network Meeting.

  • Thank Congress for Recognizing the Value of NIH in FY 2018

    You spoke and they listened, now it’s time to thank Congress for recognizing the impact that NIH and public health funding has on your research and the patients you treat. Please send a thank you message to your legislators for the 8.8% funding increase for NIH in the final FY 2018 spending bill.

  • Contact Your Senators in Support of Sickle Cell Disease Legislation

    Legislation to help improve outcomes for patients suffering from sickle cell disease (SCD) has successfully passed out of the House of Representatives and companion legislation has been introduced in the Senate. The Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018 aims to improve understanding of health care system utilization patterns of people with SCD and establish cost-effective practices to improve and extend the lives of patients.

  • Contact Your North Carolina State Senator in Support of H. 206

    The Cancer Treatment Fairness Act (H.206) would require any health plan that provides coverage for cancer chemotherapy treatment to provide coverage for orally administered and self-injectable anticancer medications at a cost no less favorable than the cost of IV, port-administered, or injected anticancer medications. It is important you reach out to ask for your North Carolina state Senator's support.

View all action alerts
  • CMS Releases National Coverage Determination on Next Generation Sequencing

    CMS released a National Coverage Determination entitled Next Generation Sequencing for Medicare Beneficiaries with Advanced Cancer. ASH submitted comments on the proposal along with over 300 other groups, including physician specialty societies, patient advocacy groups, and industry groups.

  • ASH Applauds the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018

    Senators Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018.

  • Update on Tax Reform

    On December 20, the House of Representatives and the Senate voted to approve H.R. 1, tax reform legislation. Select members of each chamber came together to resolve disagreements between the two versions passed by the House and Senate.

  • 2017 Action of the Affordable Care Act

    Congress spent much of 2017 focused on the repeal and replace of the Affordable Care Act (ACA). Included is a summary of Congress and the Administration’s actions on repeal and replace of the ACA that occurred in 2017.

View all policy news
back to top